
The transfer of the production of the dosage form started at the plant in the Technopolis Moscow SEZ
AI-generated summary
The pharmaceutical cluster in the Technopolis Moscow SEZ is being developed to ensure technological sovereignty in the field of medicine.
MOSCOW, October 11 – RIA Novosti. The production of the Russian drug for melanoma is being organized at a pharmaceutical plant in the Technopolis Moscow special economic zone; the transfer of the production of the dosage form to the site has begun, said Maxim Liksutov, Deputy Mayor of the capital for transport and industry.
He noted that pharmaceuticals are developing in the capital on behalf of Moscow mayor Sergei Sobyanin.
“The resident of the special economic zone produces a number of unique drugs on the site, including the first original Russian medicine for multiple sclerosis. Since 2021, the company has produced more than 8.5 million packages of medicines for the treatment of oncological and autoimmune diseases,” the press service of the Moscow Department of Investment and Industrial Policy quotes Liksutov as saying.
The production is carried out by Biocad. Its production complex "PK-137" is located on the territory of the Moscow SEZ and is part of the pharmaceutical cluster.
The drug contains two monoclonal antibodies – nurulimab and prolgolimab. They act on specific receptors and help the immune system find and destroy tumor cells.
To start production, company representatives will transfer and adapt technical processes, perform validation and undergo regulatory procedures. Thanks to the production of goods in the SEZ, capital patients will be able to receive medicine faster.
The enterprise complex occupies an area of 43 thousand square meters. In 2022, a plant for liquid dosage forms was opened here, and in 2024 they mastered the production of divosilimab, a drug for the treatment of multiple sclerosis.
Over the 20 years of operation of the special economic zone, the project has turned into a basic hub of Russian industry; it attracts companies that determine the technological sovereignty of the country. Ten SEZ sites are located on an area of 430 hectares. The production facilities of more than 250 high-tech enterprises are located there. The SEZ is developing the capital's department of investment and industrial policy of the city.
AI outlook — possibilities, not facts
Completion of the transfer of technical processes and completion of regulatory procedures
Likely · Within months

Specialists from the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation are studying genetic predictors of radiosensitivity and radioresistance of tumors, as well as risk factors for side effects of radiation therapy, in order to predict the effectiveness of cancer treatment and reduce the likelihood of adverse reactions in patients.

A study from the Korea University College of Medicine found that in patients with type 2 diabetes, stable body rhythms were associated with better glucose control: 46.3% of glucose targets reached with a regular regimen versus 20% with an irregular regimen, especially during physical activity between 12:00 pm and 6:00 pm.

Scientists at Nagoya University in Japan found that blocking the enzyme BCAT1 reduced the formation of scar tissue in the heart after a heart attack and preserved its pumping function in mice. The effect was observed both with genetic shutdown of the gene and with the use of the ERG240 inhibitor, even with a late start of treatment. Elevated levels of BCAT1 were detected in fibrotic tissues of patients with heart failure.

The Lancet published a study highlighting nuclear weapons and the malicious use of AI as the main threats to humanity that could lead to its extinction.

In the Amur Region, the first multidisciplinary rehabilitation center will open in December after major renovations. The first patients will be about 20 veterans of the Northern Military District. 388 million rubles were allocated to repair the facility.

Lancet experts have published a list of 17 global threats to humanity. The main risks of extinction by 2100 are the use of AI to create bioweapons and a nuclear conflict that could cause global famine.